MXPA03010380A - Uso de inhibidores de la proteasa para el virus de inmunodeficiencia humana (vih) para bloquear la migracion y/o invasion de celulas, infiltracion de tejido y formacion de edema. - Google Patents

Uso de inhibidores de la proteasa para el virus de inmunodeficiencia humana (vih) para bloquear la migracion y/o invasion de celulas, infiltracion de tejido y formacion de edema.

Info

Publication number
MXPA03010380A
MXPA03010380A MXPA03010380A MXPA03010380A MXPA03010380A MX PA03010380 A MXPA03010380 A MX PA03010380A MX PA03010380 A MXPA03010380 A MX PA03010380A MX PA03010380 A MXPA03010380 A MX PA03010380A MX PA03010380 A MXPA03010380 A MX PA03010380A
Authority
MX
Mexico
Prior art keywords
hiv
invasion
protease
inhibitors
therapy
Prior art date
Application number
MXPA03010380A
Other languages
English (en)
Inventor
Ensoli Barbara
Original Assignee
Ist Superiore Sanita
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ist Superiore Sanita filed Critical Ist Superiore Sanita
Publication of MXPA03010380A publication Critical patent/MXPA03010380A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

La presente invencion se refiere a un metodo para bloquear la invasion de celulas normales, neoplasticas inflamatorias o inmunes, infiltracion del tejido, y/o formacion de oedema a traves de la inhibicion o modulacion de moleculas y enzimas proteoliticas tales como, pero no exclusivamente, MMPs, para la terapia de todas las enfermedades cuya patogenesis se refiere a los procesos anteriores, incluyendo tumores, enfermedades angioproliferativas no neoplasticas, enfermedades inflamatorias, o enfermedades autoinmunes, el metodo se basa en el uso de loa inhibidores de la proteasa del virus VIH (VIH-PI) .
MXPA03010380A 2001-04-18 2002-04-18 Uso de inhibidores de la proteasa para el virus de inmunodeficiencia humana (vih) para bloquear la migracion y/o invasion de celulas, infiltracion de tejido y formacion de edema. MXPA03010380A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2001RM000210A ITRM20010210A1 (it) 2001-04-18 2001-04-18 Uso degli inibitori della proteasi del virus dell'immunodeficienza umana (hiv)nella terapia del sarcoma di kaposi, dei tumori e delle malatt
PCT/EP2002/004303 WO2002087583A2 (en) 2001-04-18 2002-04-18 Use of hiv-protease inhibitors to block cell migration and/or invasion, tissue infiltration and oedema formation

Publications (1)

Publication Number Publication Date
MXPA03010380A true MXPA03010380A (es) 2004-03-16

Family

ID=11455472

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03010380A MXPA03010380A (es) 2001-04-18 2002-04-18 Uso de inhibidores de la proteasa para el virus de inmunodeficiencia humana (vih) para bloquear la migracion y/o invasion de celulas, infiltracion de tejido y formacion de edema.

Country Status (14)

Country Link
US (1) US20060088545A1 (es)
EP (1) EP1401447A2 (es)
CN (1) CN1700916A (es)
AP (1) AP2003002901A0 (es)
BG (1) BG108368A (es)
CA (1) CA2447748A1 (es)
CZ (1) CZ20033113A3 (es)
EA (1) EA006678B1 (es)
EE (1) EE200300507A (es)
HU (1) HUP0401199A2 (es)
IT (1) ITRM20010210A1 (es)
MX (1) MXPA03010380A (es)
SK (1) SK14212003A3 (es)
WO (1) WO2002087583A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002346594A1 (en) * 2001-12-14 2003-06-30 Cedars-Sinai Medical Center Use of hiv-1 protease inhibitors and their derivatives in the treatment of inflammation
US7812034B2 (en) * 2003-11-04 2010-10-12 City Of Hope Method of using protease inhibitors for the treatment of liposarcomas
US20090010990A1 (en) * 2007-06-20 2009-01-08 Little Marisa A Process for depositing calcium phosphate therapeutic coatings with controlled release rates and a prosthesis coated via the process
US8741924B2 (en) 2010-05-06 2014-06-03 The Feinstein Institute For Medical Research Compounds and methods for treatment of systemic lupus erythematosus
CA2822639A1 (en) * 2010-12-22 2012-06-28 The Feinstein Institute For Medical Research Methods for treating systemic lupus erythematosus using hiv protease inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2779653B1 (fr) * 1998-06-11 2002-12-20 Inst Nat Sante Rech Med Utilisation de composes modulateurs du proteasome en therapie
AU1930900A (en) * 1998-12-04 2000-06-26 University Of Maryland Biotechnology Institute Use of protease inhibitors to modulate cellular pathways, immunity and therapiesassociated therewith

Also Published As

Publication number Publication date
SK14212003A3 (sk) 2004-06-08
BG108368A (bg) 2005-01-31
ITRM20010210A0 (it) 2001-04-18
ITRM20010210A1 (it) 2002-10-18
HUP0401199A2 (hu) 2004-12-28
EP1401447A2 (en) 2004-03-31
CA2447748A1 (en) 2002-11-07
US20060088545A1 (en) 2006-04-27
AP2003002901A0 (en) 2003-12-31
CZ20033113A3 (cs) 2004-07-14
CN1700916A (zh) 2005-11-23
WO2002087583A3 (en) 2002-12-19
EE200300507A (et) 2004-02-16
EA006678B1 (ru) 2006-02-24
EA200301130A1 (ru) 2004-04-29
WO2002087583A2 (en) 2002-11-07
WO2002087583B1 (en) 2003-11-20

Similar Documents

Publication Publication Date Title
DE69826695D1 (de) Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
ATE286053T1 (de) Naphthyridinone zur hemmung der durch protein- tyrosin-kinase und zellzyklus kinase hervorgerufenen zellvermehrung
DK0833839T3 (da) Heterocykliske peptidylforbindelser, der er nyttige til behandling af thrombinrelaterede sygdomme
ATE380548T1 (de) Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie
BR0013966A (pt) Compostos espiroeterocìclicos úteis como inibidores reversìveis de proteases de cisteìna
MX9800146A (es) Nuevos inhibidores de trombina, su preparacion y su uso.
NO983688L (no) Serin-protease-inhibitorer
ATE335485T1 (de) Quinolin-enthaltende alpha-ketoamid-basierte inhibitoren von cystein- und serin protease
TR199902766T2 (xx) Proteaz inhibit�rleri.
BR9612360A (pt) Inibidores de amidino protease
HK1025511A1 (en) Peptidyl-2-amino-1-hydroxyalkanesulfonic acid cysteine protease inhibitors
MXPA03010380A (es) Uso de inhibidores de la proteasa para el virus de inmunodeficiencia humana (vih) para bloquear la migracion y/o invasion de celulas, infiltracion de tejido y formacion de edema.
ATE415961T1 (de) Therapeutische verwendung von mitgliedern der n,n-dicylcohexyl-2-hydroxy-7,7- dimethylbicycloä2.2.1ühept-1- ylmethanesulphonamide-familie
ES2072280T3 (es) Enzimas catabolicas para la induccion del factor de necrosis tumoral (tnf).
HUP9802531A2 (hu) Eljárás haematopoeticus stem sejtek mobilizálására
DE69333689D1 (de) Inhibitorresistente serinproteasen
DE69332904D1 (de) Hemmung von hiv-infektion
TR199801492A2 (xx) S�lfonamid-ikame etmi� bile�ikleri elde etme usulleri.
DE60015559D1 (de) Sentrin-spezifische menschliche protease senp1
GB2385854A (en) Type III secretion pathway in aeromonas salmonicida and uses therefor
DK1096951T3 (da) Anvendelse af bromelainproteaser til inhiberingen af blodkoaguleringen
FR2813606B1 (fr) Proteine bard1 tronquee, et ses applications diagnostiques et therapeutiques
HUP0402246A2 (hu) Leukocitaintegrinek új peptidligandjai
WO2003072724A3 (en) Human analogs of murine deubiquitinating protease genes
DE59813159D1 (de) Kombination der proteolytischen enzyme trypsin, bromelain und papain zur behandlung von glomerulonephritis

Legal Events

Date Code Title Description
FA Abandonment or withdrawal